What's the SCORE with triamcinolone?

Article

Triamcinolone acetonide injections for macular oedema associated with retinal vein occlusion have become a therapeutic mainstay, but conflicting data has emerged about the safety of these injections, and some reports indicate that visual stabilization rather than visual improvement is occurring, according to research presented at the 2006 meeting of the AAO in Las Vegas.

Triamcinolone acetonide injections for macular oedema associated with retinal vein occlusion have become a therapeutic mainstay, but conflicting data has emerged about the safety of these injections, and some reports indicate that visual stabilization rather than visual improvement is occurring, according to research presented at the 2006 meeting of the AAO in Las Vegas.

The Standard Care versus Corticosteroid for Retinal Vein Occlusion (SCORE) study has been launched to provide long-term data on the safety and efficacy of this treatment approach, and more than 400 patients have now been enrolled at 82 clinical sites, according to Ingrid U. Scott, MD, MPH, professor of ophthalmology and health evaluation science, Penn State College of Medicine, USA.

"This is expected to be a definitive trial on the role of intravitreal triamcinolone for macular oedema associated with retinal vein occlusion with a one year primary outcome assessment," Dr Scott remarked.

SCORE is a randomized, controlled, multicentre Phase III trial that began in 2003 and is funded by the National Eye Institute. Separate trials are being conducted under the SCORE umbrella for central retinal vein occlusion and for branch retinal vein occlusion. In both trials, patients are randomized 1:1:1 to 1 mg of steroid, 4 mg of steroid, or standard care.

"The SCORE study is a collaborative effort among ophthalmologists in both private practice and academia, the National Eye Institute, regulatory agencies, and an industry partner. This study provides us the opportunity to find an effective treatment for patients with central retinal vein occlusion and a more effective treatment for branch retinal vein occlusion," Dr Scott said.

Intravitreal corticosteroid injections for macular oedema associated with retinal vein occlusion were introduced in 1999, and initial reports appeared promising, with dramatic improvements in macular oedema and visual acuity in some patients to a level that had not been previously reported, Dr. Scott said. This therapeutic intervention was widely adopted, but the relative lack of long-term follow-up data and new questions about safety and effectiveness prompted the design of the SCORE study.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Christine Curcio, PhD, of the University of Alabama at Birmingham Heersink School of Medicine, shares histology update and revised nomenclature for OCT with Sheryl Stevenson of the Eye Care Network and Ophthalmology Times
SriniVas R. Sadda, MD, FARVO, shares key points from his retina presentation at the International SPECTRALIS Symposium
Robert Sergott, MD, describes fluorescence lifetime imaging ophthalmoscopy (FLIO) and the International SPECTRALIS Symposium – And Beyond (ISS) in Heidelberg, Germany.
Rayaz Malik, MBChB, PhD, a professor of medicine at Weill Cornell Medicine - Qatar, spoke with Ophthalmology Times Europe about his presentation. It's titled "An eye on neurodegenerative diseases: Challenging the dogma" at the International SPECTRALIS Sympsoium. In conversation with Hattie Hayes, Ophthalmology Times Europe
Anat Loewenstein, MD, describes her presentation on remote imaging for age-related macular degeneration and geographic atrophy at the International SPECTRALIS Symposium, in conversation with Hattie Hayes of Ophthalmology Times Europe
Tyson Brunstetter, OD, PhD, a US Navy Aerospace Optometrist at the NASA Johnson Space Center in Houston, Texas, shares key takeaways from his keynote at the International SPECTRALIS Symposium (ISS)
Rayaz Malik, MBChB, PhD, shares his presentation, titled An eye on neurodegenerative diseases: Challenging the dogma, at this year's International SPECTRALIS Symposium
At the Retina World Congress, Siegfried Priglinger, MD, speaks about ensuring the best outcomes for preschool-aged patients
At the 2025 ASCRS meeting, Robert Ang, MD said small aperture IOLs can benefit all patients, especially those with complex corneas or who have undergone previous corneal refractive surgery
© 2025 MJH Life Sciences

All rights reserved.